A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Retreatment
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
Inclusion Criteria:
Exclusion Criteria:
CABA, C1425DKG, Argentina
Wuhan, 430022, China
Borgyogyaszati Klinika, 7632, Hungary
Szeged, 6720, Hungary
Itabashi Ku, 173 8606, Japan
Kitakyushu-shi, 807-8556, Japan
Osaka Sayama Shi, 589 8511, Japan
Elblag, 82 300, Poland
Krakow, 30-002, Poland